Orthopoxviruses encode multiple proteins that modulate host immune responses. We determined whether cowpox virus (CPXV), a representative orthopoxvirus, modulated innate and acquired immune functions of human primary myeloid DCs and plasmacytoid DCs and monocyte-derived DCs (MDDCs). A CPXV infection of DCs at a multiplicity of infection of 10 was nonproductive, altered cellular morphology, and failed to reduce cell viability. A CPXV infection of DCs did not stimulate cytokine or chemokine secretion directly, but suppressed toll-like receptor (TLR) agonist-induced cytokine secretion and a DC-stimulated mixed leukocyte reaction (MLR). LPS-stimulated NF-κB nuclear translocation and host cytokine gene transcription were suppressed in CPXV-infected MDDCs. Early viral immunomodulatory genes were upregulated in MDDCs, consistent with early DC immunosuppression via synthesis of intracellular viral proteins. We conclude that a nonproductive CPXV infection suppressed DC immune function by synthesizing early intracellular viral proteins that suppressed DC signaling pathways.
Introduction
Orthopoxviruses are a genus of poxviruses that include among others the virulent human pathogen variola virus (VARV), the agent of smallpox, as well as monkeypox virus (MPXV), cowpox virus (CPXV) and vaccinia virus (VACV), the latter two viruses comprising the original vaccines, which led to the eradication of smallpox. The success of these vaccines suggests that new vaccines using vaccinia virus as the vaccine platform may provide protection against a number of other diseases. Paradoxically, poxviruses such as vaccinia virus encode a large number of immunomodulatory proteins including both intracellular and secreted proteins that have the potential to modify the host responses to the primary orthopoxviral infection as well as to secondary infections (reviewed by Seet et al., 2003) . Many of these proteins can interfere with the effectiveness of the viral vaccines, indicating that a better understanding of orthopoxvirus interactions with the host immune response will help us to improve orthopoxvirus vectors for use as viral vaccines.
One mechanism that VACV exploits to modulate host immunity is to infect dendritic cells (DCs) and inhibit their ability to perform various innate and adaptive immune functions (Deng et al., 2006; Drillien et al., 2000; Jenne et al., 2001; Yao et al., 2007) . Indeed, among cells of the immune system, vaccinia viruses preferentially infect monocytes and DCs (Liu et al., 2008; Sanchez-Puig et al., 2004; Yu et al., 2009) . As innate immune cells, both myeloid DCs (mDCs, also referred to as conventional DCs) and plasmacytoid DCs (pDCs) recognize pathogen-associated molecular patterns (PAMPs) using toll-like receptors (TLRs) and other pattern recognition receptors (PRRs) and respond by secreting cytokines and chemokines that Virology 412 (2011) 411-425 participate in the nonimmune host defense against the pathogen (reviewed in Kaisho and Akira, 2003) . As cells also responsible for initiating adaptive immunity, DCs avidly take up and process antigen and, after appropriate perturbation through their pattern recognition receptors (PRRs), mature and migrate to regional lymph nodes where they present antigen in the context of MHC class II to stimulate naïve CD4 T cells to divide and differentiate (reviewed in Lipscomb and Masten, 2002) . Therefore, if an orthopoxvirus infected sufficient numbers of DCs in vivo, it might be expected to compromise the host's ability to protect itself against the primary viral infection as well as to any secondary infectious agent that might challenge the host during the orthopoxvirus infection.
CPXV naturally infects wild rodents, including mice, and incidentally infects humans (Bennett et al., 1997; Chantrey et al., 1999; Crouch et al., 1995; Vorou et al., 2008) . Cowpox infections in Europe among younger individuals have been increasingly reported, because smallpox vaccination is no longer routine (Vorou et al., 2008) . The virus has a larger genome than VACV and encodes more immunosuppressive molecules than VACV (Gubser et al., 2004; Meyer et al., 2002) , so we asked whether CPXV, as described for VACV, might suppress the immune function of human monocyte-derived DCs (MDDCs). We also, for the first time, examined the effect of an orthopoxvirus infection on primary peripheral blood mDCs and pDCs. We found that although CPXV infection of DCs was nonproductive and failed to kill the cells, it profoundly suppressed both innate and acquired immune function of all three subsets of DCs. Therefore, we performed additional studies to determine the mechanisms.
Results

CPXV infection of human DCs is not productive and does not alter cell viability, but does alter cellular morphology
We first asked whether CPXV infection of human DCs resulted in viral progeny (a productive infection) and resulted in eventual lysis of the cells. CPXV infection of a standard permissive cell line, VeroE6 at a moi of 10 led to a productive infection with lysis of the monolayer within 24 h (data not shown). In contrast, infection of MDDCs and primary mDCs and pDCs resulted in no increase in viral progeny (Supplemental Fig. 1 ) and no more cell death at 24 h or 5 d than did culture in medium only (Table 1) . However, a nonpermissive infection with orthopoxviruses might still allow for viral DNA replication with the generation of late protein production, and the production of viral inclusions such as the production of A-type inclusions (Patel et al., 1986) , even though mature viral assembly does not occur. Furthermore, poxvirus infections have been associated with disruption of the cell cytoskeleton leading to morphologic changes in the infected cells (Cudmore et al., 1995; Ward and Moss, 2001) . MDDCs from in vitro culture demonstrated typical dendrites (Fig. 1A) , while mDCs and pDCs freshly isolated from peripheral blood exhibited few distinguishing features aside from their monocytoid and plasmacytoid appearances, respectively (Figs. 1B and C.) . After overnight culture of MDDCs, mDCs and pDCs in medium only (Figs. 1D, E, and F, respectively) or with TLR agonists in medium (Figs. 1G, H, and I) , dendritic projections became more pronounced and punctate cytoplasmic vesicles formed in all DCs, characteristics associated with normal DC maturation. In contrast, DCs treated with CPXV (Figs. 1J, K and L) did not demonstrate these features of maturation. CPXVexposed MDDCs demonstrated more extensive cytoplasmic vacuole formation and loss of dendrites with the formation of syncytial cells in up to 20% of the cells (Fig. 1J shows a bi-nucleated MDDC). mDCs exposed to CPXV demonstrated excessive vacuolation, loss of dendrites, and, in 24% of the cells, cytoplasmic eosinophilic inclusions, characteristic of A-type inclusions (Fig. 1K ). pDCs exposed to CPXV formed fewer large vacuoles as compared to mDCs, but also formed eosinophilic inclusions similar to those in mDCs in 24% of cells (Fig. 1L ). Neither mDCs nor pDCs formed syncytia, while MDDCs failed to demonstrate eosinophilic cytoplasmic inclusions. The morphologic changes were consistent with a nonpermissive infection of all three DC subsets, with typical A-type inclusions evident in some of the mDCs and pDCs.
CPXV infection of DCs fails to stimulate cytokine secretion and inhibits TLR-induced cytokine secretion
An orthopoxvirus infection, even if non-permissive, could allow synthesis of viral immunomodulatory proteins that might interfere with DC responses to the infecting virus as well as to exogenous stimuli. We asked whether CPXV directly interacted with PRRs and stimulated production of cytokines and chemokines from MDDCs, mDCs and pDCs. mDCs and pDCs isolated directly from human peripheral blood and MDDCs generated in culture were incubated for 24 h in medium as a negative control, with appropriate TLR agonists (as a positive control) or with CPXV. In humans, MDDCs and mDCs express TLR4 while pDCs strongly express TLR7. Therefore, LPS was used to stimulate MDDCs and mDCs through TLR4, and influenza A was used to stimulate pDCs through TLR7.
CPXV exposure failed to stimulate secretion of any of 23 cytokines analyzed in initial experiments from any of the DC types (see Materials and methods for a complete list). In contrast, LPS stimulated the secretion of the cytokines IL-1β, IL-6, IL-10, IL-12p40, MIP-1α and TNFα from MDDCs and mDCs while influenza A stimulated pDCs to secrete IFNα, MIP-1α and TNFα. MDDCs, mDCs and pDCs failed to consistently secrete any of the remaining 23 cytokines tested in response to their relevant agonist. For simplicity, for MDDCs and mDCs, we show data for IL-12p40 and TNFα, two cytokines often produced in response to TLR agonists by mDCs, and MIP-1α, a chemokine that has phagocyte stimulating and proinflammatory properties (Figs. 2A, B, D , E, G, H) . For pDCs, we show data for IFNα, a hallmark anti-viral response of pDCs, MIP-1α, and TNFα (Figs. 2C, F, I ). The failure of CPXV to induce cytokine secretion might reflect either lack of stimulation or suppression that overrides any stimulatory effects. Therefore, we asked whether CPXV suppressed the response to a strong TLR agonist by adding CPXV to DC cultures at the same time the TLR agonist was added. TLR agonist-induced secretion of all cytokines by MDDCs, mDCs and pDCs was significantly suppressed by the presence of CPXV in culture (Figs. 2A-I and data not shown).
If DC suppression resulted from the synthesis of viral immunosuppressive proteins, it would be expected that live virus would be required to demonstrate the interference with TLR agonist-induced cytokine secretion. The virus was heat inactivated (hi) and added to DC cultures at the same time that the TLR agonist was added. The hiCPXV did not stimulate cytokine secretion from DCs nor did hiCPXV suppress TLR agonist stimulated cytokine secretion from MDDCs, mDCs or pDCs (Figs. 2A-I and data not shown). Data is expressed as percent viable cell recovered at 24 h or after a 24 h exposure to virus + 5 additional days of incubation divided by the initial viable DCs placed in culture with the treatments shown × 100 ± STD. Viability was determined by trypan blue exclusion.
One explanation for the suppressed levels of TNFα and MIP-1α in CPXV-infected MDDC, mDC and pDC supernatants and for IFNα in pDC supernatants was that the conditioned medium contained virally encoded immunomodulators that might interfere with their detection, i.e., receptors for TNFα (vTNFR), the viral CC chemokine inhibitor (vCCI) or a receptor for IFNα (Colamonici et al., 1995; Loparev et al., 1998; Smith et al., 1996; Symons et al., 1995) . Therefore, we assayed TNFα, MIP-1α and IFNα standards (and IL-6, IL-10 and IL-12 standards as controls) in "conditioned" medium collected from CPXVinfected MDDCs and pDCs (or in medium from uninfected DCs as a control) from four different donors for each DC type. Addition of conditioned medium from MDDCs and pDCs to standards did not interfere significantly with quantitation of TNFα or , suggesting that either the relevant secreted viral factors were not present or that secreted viral products did not interfere with the assay for human TNFα and MIP-1α in MDDCs and pDCs. However, both CPXV-infected MDDC and pDC conditioned medium reduced detection of the IFNα standard by variable degrees depending on the conditioned supernatant (Figs. 3A and B) . Since, in our hands MDDCs did not secrete IFNα in response to LPS, this interference with detection of IFNα in CPXV-infected cells was less relevant, but the suppressed values of IFNα in 24 h supernatants from influenza Atreated, CPXV-infected pDCs could have resulted from interference with detection by a viral IFNα receptor secreted into the cultures. However, in two of the four samples examined, the percent suppression of IFNα secretion in the influenza A-treated, CPXVinfected pDCs supernatants was greater than the percent interference by vIFNα of the IFNα standard detection (data not shown). Thus, we Fig. 1 . Human DCs exposed to CPXV exhibit altered morphology. MDDCs, mDCs and pDCs were either unexposed (T = 0, top row), medium-exposed for 24 h (T = 24 h, second row), TLR agonist-exposed for 24 h (T = 24 h, third row, to LPS for MDDCs and mDCs and to influenza A for pDCs) or CPXV-exposed for 24 h (T = 24 h, fourth row). A. MDDCs from in vitro culture demonstrated typical dendrites and single nuclei. B. Freshly isolated peripheral blood mDCs exhibited few distinguishing features aside from their monocytoid appearances. C. Freshly isolated peripheral blood pDCs demonstrated a plasmacytoid appearance. D. MDDCs after 24 h culture in medium demonstrated dendrites relatively unchanged from prior to overnight culture. E. mDCs after a 24 h culture in medium developed more dendrites F. pDCs after a 24 h culture appeared unchanged. G. MDDCs treated for 24 h with LPS showed similar dendrite formation, but larger vacuoles as compared to those that were incubated overnight in medium. H. mDCs cultured overnight in LPS showed increased dendrite and vacuole formation as compared to those incubated in LPS-free medium. I. pDCs cultured with influenza A showed increased formation of surface projections with some dendrites as compared to pDCs culture overnight in virus-free medium. J. MDDCs cultured 24 h with CPXV showed blebbing and loss of dendrites with increased numbers of vacuoles. A subpopulation showed multi-nucleation; shown here is as a bi-nucleated MDDCs. K. mDCs exposed 24 h to CPXV also demonstrated excessive vacuolation, loss of dendrites and surface blebbing, and, in 24% of the cells, cytoplasmic eosinophilic inclusions, characteristic of A-type inclusions. L. pDCs exposed to CPXV for 24 h formed fewer large vacuoles as compared to mDCs, but 24% of them contained eosinophilic inclusions similar to those in mDCs. Large arrows identify membrane blebs (J and K); small arrows identify vacuoles (J and L) and arrowheads identify viral inclusions (K and L). All cells were photographed with a 63× objective.
concluded that CPXV infection of pDCs suppressed their capacity to secrete TNFα and MIP-1α, and at least in some donors, the virus might have at least partly suppressed secretion of IFNα.
CPXV infection of MDDCs did not suppress LPS-induced cytokine secretion at a moi of 0.01 or 0.1, and only variably suppressed secretion at a moi of 1.0 (data not shown). Thus, it was possible that Fig. 2 . CPXV infection does not stimulate DC chemokine/cytokine secretion and inhibits DC secretion in response to TLR agonists. Human MDDCs (A, D, G), mDCs (B, E, H), and pDCs (C, F, I) were exposed to medium only, a representative TLR agonist (for MDDCs and mDCs, LPS; for pDCs, influenza A, CPXV, CPX + TLR agonist, hiCPXV or hiCPXV + LPS) for 24 h. Supernatants for all experiments were assayed for the secretion of IL-1β, IL-10, IFNα, IL-6, IL-12p40, MIP-1α and TNFα, but only IL-12p40 (A, B, C), MIP-1α (D, E, F), TNFα (G, H for MDDCs) and IFNα (I for pDCs) are shown. Data are an average of 7 independent experiments for medium, LPS, CPXV, and CPXV + TLR-agonist treated DCs and 3 independent experiments for hiCPXV and hiCPXV + TLR agonist-treated DCs. Statistical analysis one-way ANOVA *p b 0.05 and **p b 0.01. Statistical comparisons were between TLR agonisttreated DCs and CPXV + TLR agonist-treated DCs. Fig. 3 . Supernatants from CPXV-infected MDDCs (A) and pDCs (B) interfere with the detection of IFNα. MDDCs (n = 4) and pDCs (n = 4) were infected with CPXV at MOI 10. Supernatants were collected, and then incubated in triplicate with a standard containing a mixture of the following cytokines: IL-10, IFNα, IL-6, IL-12p70, MIP-1α, and TNFα. The "percent detected MDDCs/pDCs" was derived as pg/ml cytokine/chemokine in infected DC supernatants divided by pg/ml cytokine of standard in uninfected DC supernatants × 100. Data is the average of 4 experiments ± SEM except for MIP-1α for MDDCs where n = 3. the DC suppression required direct infection of the majority of exposed DCs. The virus-encoded cytokine response modifier A (CrmA), which is an early protein , can be detected in virus-infected cells using a polyclonal rabbit anti-CrmA antisera. To assess percent infected DCs at the moi that induced suppression, CPXV was added to MDDCs at increasing moi, incubated for 6 h and probed by immunofluorescence for the presence of CrmA (Supplemental Fig. 2 demonstrates both CrmA-positive and negative cells). The percent CrmA-positive MDDCs was as follows: at a moi 0; 0.0% (SD ± 0.0%), at a moi 0.01; 3.0% (±0.5%), at a moi 0.1; 7.8% (±0.8%), at a moi 1.0; 44.0% (±2.5%) and at a moi 10; 90.5% (±5.8%). Thus, a moi of 10, which was consistently associated with profound suppression of LPS-induced cytokine secretion of MDDCs, resulted in infection of most DCs, consistent with the suppression being due to direct infection rather than an effect of soluble factors secreted by the infected DCs. We did not specifically assess CrmA-positive cells in mDCs or pDCs at a moi of 10, but presume, based on the presence of viral inclusions in 24% of these cells that this would be minimum infection rate and based on the nearly uniform morphologic differences in infected versus uninfected mDCs and pDCs that a 90% infection rate in the cells would be likely.
CPXV infection of DCs inhibits their stimulation of allogeneic CD4+ T cell proliferation
The adaptive immune capacity of human MDDCs, mDCs and pDCs following overnight exposure to CPXV was assessed in a mixed lymphocyte reaction (MLR). MDDCs incubated in medium or pretreated with LPS stimulated allogeneic CD4+ T cell proliferation, and LPSexposed DCs typically stimulated greater proliferation than mediumexposed DCs (Fig. 4A) . In contrast, mDCs incubated overnight in medium without LPS typically promoted greater proliferation than those pretreated with LPS (Fig. 4B) . However, neither MDDCs nor mDCs infected with CPXV overnight were capable of stimulating allogeneic T cells (Figs. 4A and B) . Furthermore, LPS added with CPXV to DCs during the 24 h pretreatment period did not enhance the capability of infected MDDCs or mDCs to stimulate a MLR (Figs. 4A and B) . Although not as potent as mDCs in stimulating allogeneic T cells, the ability of pDCs to promote a MLR was also completely suppressed if they were preexposed to CPXV overnight (Fig. 4C ). Both medium-treated and influenza A-treated pDCs promoted proliferation of CD4+ T cells, and adding influenza to CPXV+ pDC cultures during the 24 h pre-exposure period did not enhance the ability of infected pDCs to stimulate a MLR. We asked whether live virus was required for suppression of a MLR using MDDCs. MDDCs pretreated with hiCPXV stimulated a MLR similar to MDDCs cultured overnight in medium only and MDDCs pretreated with hiCPXV plus LPS also promoted T cell proliferation comparable to LPS-preexposed MDDCs (Fig. 4A) . Finally, we asked whether the inability of CPXV-infected DCs to stimulate a MLR resulted from a direct effect of the virus carried into culture on the responder T cells. Therefore, we added the number of CPXV virions comparable to the number that would be carried into culture by CPXV-infected DCs to CD4+ T cell cultures stimulated with PMA and PHA (data not shown). There was no effect of the added live CPXV on T cell stimulation indicating that the failure of DC to stimulate T cells in the MLR was not due to CPXV infection of T cells.
CPXV infection of DCs inhibits their phenotypic maturation
One explanation for the poor MLR stimulation by DCs infected with CPXV (both with and without LPS co-exposure) was that infected DCs were unable to increase their expression of co-stimulatory molecules and HLA-DR. We assessed these molecules on MDDCs, mDCs and pDCs at 0 time and after 24 h exposure to CPXV in the presence or absence the relevant TLR agonist. We examined MDDCs and mDCs for the expression of CD80, CD86, CD40 and HLA-DR, and pDCs were examined for the presence of CD80, CD86, HLA-DR and BDCA2, the latter known to decrease on pDCs as they mature (Dzionek et al., 2000) . The percent of CD80 and CD86-positive MDDCs, mDCs and pDCs were significantly decreased between CPXV-exposed and medium-exposed cells and between CPXV+ LPS-exposed and LPS only-exposed cells (Figs. 5A-C). Although the percentage of HLA-DR-positive MDDCs, mDCs and pDCs was unaffected regardless of treatment, the mean fluorescence intensity of HLA-DR was decreased on all three DC types if they were CPXV-exposed as compared to when they were medium-treated as well as if they were CPXV+ LPS-treated as compared to LPS-treatment only, although the decrease did not reach significance for the MDDCs (Figs. 5D-F). The percentage of CD40-positive MDDCs was unaffected independent of treatment, but for mDCs, there was a significant decrease in the percent CD40-positive mDCs if they were treated with CPXV as compared to medium exposure only (Fig. 5B ). For pDCs, as expected, BDCA2 on pDCs decreased during overnight incubation with medium only or in the presence of influenza A, but incubation with CPXV suppressed partially the down-regulation (Fig. 5C ). Thus, CPXV infection of DCs generally suppressed the expression of molecules known to be important in stimulating T cells to respond in a MLR, although these observations may not fully explain the profound suppression of T cell proliferation.
CPXV infection of MDDCs inhibits LPS-induced cytokine mRNA synthesis and nuclear translocation of NF-κB
It was important to begin to dissect the mechanisms of suppression caused by infecting DCs at a moi of 10. Because our findings were similar among all three DC types and MDDCs are more readily available in sufficient numbers, we used these cells for subsequent studies. CPXV expresses over 20 immune evasion genes in permissive cell lines that could contribute either intracellular or secreted gene products that could potentially suppress DC immune function. If any or a combination of them would be expected to play a role, then the MVA strain in which only few immunomodulatory genes remain intact should not suppress DC function. MVA (moi = 10) was added to MDDCs with and without LPS for 24 h. MVA failed to stimulate IL-12, TNFα or MIP-1α secretion by MDDCs, and MVA also failed to suppress the LPS-stimulated cytokine response in MDDCs (Supplemental Fig. 3 ). This finding is consistent with one or more CPXV genes being responsible for the complete suppression of LPSinduced cytokine secretion by human DCs. A number of viral immune evasion genes have been reported to interfere with NF-κB-dependent transcriptional activation Oie and Pickup, 2001 ). We asked whether one mechanism by which CPXV inhibited LPS-induced cytokine and chemokine secretion in MDDCs was to prevent cytokine and chemokine gene transcription and NF-κB nuclear translocation. MDDCs were exposed to medium, LPS or CPXV + LPS, and total RNA was extracted at 0, 1, 2, 4, 6, 12 and 24 h post-exposure. Real-time RT-PCR was performed and the fold-change for TNFα, MIP-1α and IL-12 transcript levels over 0 h was determined. LPS stimulation of MDDCs led to significant induction of these three cytokine transcripts over 24 h as compared to unstimulated control MDDCs (Fig. 6 ). The TNFα transcripts in LPS-treated MDDCs peaked at 1 h post-exposure and remained at an average of 35-fold higher than the 0 h time point with a marked reduction at 24 h post-exposure (Fig. 6A) . Although, CPXV + LPS co-treated MDDCs also showed an increase in TNFα transcripts at 1 h and 2 h post-exposure, the levels were significantly lower than LPS-treated, but uninfected MDDCs. Similarly, MIP-1α transcripts in Fig. 5 . CPXV inhibits the expression of maturation markers on DCs. Four-color flow cytometric analysis of HLA-DR and the co-stimulatory molecules CD80, CD86 and CD40 was performed on untreated MDDCs (A) and mDCs (B) and after overnight incubation with medium, LPS, CPXV and CPXV + LPS. Expression of HLA-DR, BDCA2 and the costimulatory molecules CD80 and CD86 was performed on untreated pDCs and then following overnight incubation with medium, influenza A, CPXV and CPXV + influenza A (C). MFI of HLA-DR was analyzed on MDDCs (D), mDCs (E) and pDCs (F) under the same conditions as above. Data shown are an average of three independent experiments for untreated DCs and four independent experiments for all other experimental conditions. Statistical analysis one-way ANOVA *p b 0.05, **p b 0.01 and ***p b 0.001. Statistical comparisons were between medium-treated DCs and CPXV-exposed DCs and between TLR agonist-treated DCs and CPXV + TLR agonist-treated DCs.
LPS-treated MDDCs displayed a peak fold-change at 4 h post-exposure with an average of 88-fold higher than 0 h, but the CPXV + LPS treated MDDCs failed to induce MIP-1α transcripts (Fig. 6B) . Finally, the IL12p40 transcripts in LPS-treated MDDCs peaked at 6 h post-exposure with an average 196-fold higher than at 0 h. Although in CPXV + LPStreated MDDCs, IL12p40 transcripts were induced, the levels were significantly lower than in LPS-induced MDDCs (Fig. 6C) . Thus, the coexposure of MDDC with CPXV + LPS resulted in significant suppression of LPS-induced transcription of all three cytokines as early as 1 h post-exposure compared to the LPS-treated MDDCs. These studies were consistent with live CPXV viral particles, early viral transcripts and/or viral proteins made very early in infection being responsible for inhibiting viral host cell cytokine/chemokine gene transcription.
Because transcription of TNFα, MIP-1α and IL-12p40 require NF-κB activation, we asked whether the inhibition of LPS-induced cytokine transcription by CPXV infection was associated with suppression of nuclear translocation of NF-κB. MDDCs were exposed to LPS or CPXV + LPS, incubated for 0, 1, 2 and 4 h and immunostained to detect whether NF-κB was in the nucleus (Supplemental Fig. 4) . At 1 h post-exposure, there was a small difference in the presence of NF-κB in the nucleus of MDDCs between LPS-treated MDDCs and CPXV + LPS treated MDDCs (Table 2) . By 2 h post-exposure, while NF-κB was again detected in the nucleus of nearly all LPS-treated DCs, 20% of CPXV + LPS-treated MDDCs demonstrated nuclear NF-κB. By 4 h, fewer than 5% of MDDCs treated with CPXV + LPS demonstrated nuclear NF-κB while the majority of LPS-treated MDDC continued to demonstrate nuclear NF-κB. These studies demonstrate that CPXV infection of human DCs disrupts sustained retention of NF-κB in the nucleus induced in MDDCs by LPS stimulation.
A representative CPXV immune evasion protein, CrmA, is detected in MDDCs 2 h post infection
We speculated that the inhibition of LPS-induced NF-κB nuclear translocation and cytokine gene transcription was the result of accumulation of one or more viral immunomodulatory proteins within the cytoplasm. CrmA protein, a viral inhibitor of caspase-1 (Ray et al., 1992) , was readily detected in DC cytoplasm at 6 h post infection as shown in the study to investigate the number of DCs infected at various moi (Supplemental Fig. 2 ). Therefore, we assessed the time course for expression of CrmA protein in MDDCs at a moi of 10. CrmA was readily detected by western blot 2 h post-infection and continued to accumulate through a 12 h time course (Fig. 7) . The detection of CrmA by 2 h was compatible with the possibility that other early viral transcripts of immune evasion genes might be translated within 2 h and these proteins could interfere with host cytokine gene transcription.
CPXV transcripts of immunomodulatory genes are present in infected MDDCs
As shown above, 90% of MDDCs were infected at a viral moi of 10 as determined by the detection of the viral immunomodulatory protein, CrmA, in the cytoplasm. However, it was important to assess expression of other immunomodulatory orthopoxvirus genes that encode proteins more relevant to early interference with signaling a MDDCs were exposed to LPS or LPS and CPXV. At the times shown, the cells were collected in suspension, cytocentrifuged onto glass slides, fixed and stained with rabbit polyclonal anti-NF-κBp65, and mounted as described in Materials and methods to counterstain nuclear DNA with DAPI which yields a blue diffuse nuclear fluorescence to identify the nucleus. For each variable, 100 cells were counted to identify green fluorescence against a background of blue (see Supplemental Fig. 4 for examples). Data is expressed as the average ± SD for three separate experiments. b Only one data point was available for this time point.
through a TLR. MDDCs and VeroE6 cells, the latter to control for transcription of the full repertoire of viral genes, were either untreated as negative hybridization controls or exposed to CPXV at a moi of 10. The transcriptomes of CPXV at 0 time (after cell exposure to virus in the cold followed by warming to room temperature) and 0.5, 1, 2, 4 and 12 h were assessed using a CPXV-specific microarrays. All transcripts that were expressed 2.5 fold above 0 time at each of the time points assessed were identified and are listed in Supplemental Table 1 together with the homologous VACV Copenhagen (COP) gene designation, the putative gene function, the functional gene class and the fold increase above 0 time. In Table 3 , we summarized data from Supplemental Table 1 to show at each time point the number of genes expressed at 2.5 fold above 0 time that encoded proteins of one of six functional classes, i.e., 1) DNA replication, 2) transcription, 3) immune evasion/virulence (or immunomodulatory), 4) virion core proteins, 5) membrane proteins and 6) unknown/other. Expression of immune evasion/virulence genes was already present at 0.5 h (20 genes), increased by 1 h (40 genes) and continued through 12 h. The genes expressed (Supplemental Table 1 ) included those that encode proteins that could accumulate within infected cells and potentially either disrupt TLR signaling e.g. CPXV-BR_184/VACV-A46R and CPXV-BR_190/VACV-A52R (Bowie et al., 2000) or interfere with NF-κB activation and subsequent nuclear translocation e.g. CPXV-BR_41/ VAVC-K1L (Lynch et al., 2009; Shisler and Jin, 2004) . Furthermore, many expressed genes also encode proteins that are secreted and, therefore, could exert effects on cells in the microenvironment or interfere with detection of cytokines or chemokines in supernatants, such as the viral chemokine inhibitor vCCI (CPXV-BR_03/227) and the one that we detected, IFN α/β receptor (CPXV-BR_212) (Supplemental Table 1 ). The microarray data also demonstrated that many late genes encoding structural proteins were transcribed in CPXV-infected MDDCs, although the infection was nonpermissive, compatible with a block in a productive infection that was post-DNA replication.
Discussion
Orthopoxviruses are complex enveloped dsDNA viruses that replicate in the cytoplasm in a cell-cycle independent fashion, and unlike most viruses, largely independent of host cellular mechanisms (Moss, 2007) . Their immunomodulatory genes were acquired via a process of co-evolution with their relevant host to circumvent the host immune response to viral infections (reviewed in Bugert and Darai, 2000; Pickup, 2007; Seet et al., 2003) . These viral genes encode homologs of human cytokines, cytokine receptors, complement inhibitors, and other protein binding molecules that either function within the infected host cell or are secreted whereby they can affect other cells in the microenvironment. In this study, we chose to use CPXV to determine the effects of orthopoxviruses upon human MDDCs, because CPXV possesses one of the most extensive sets of the accessory genes present in the genomes of the various orthopoxviruses, suggesting that it may have more extensive control over DC functions than viruses such as vaccinia virus. Although the effects of VACV on human MDDCs has been examined, a more in depth examination of the immunomodulatory effect of CPXV on human MDDCs was warranted, particularly in view of continuing zoonotic infections of humans with this virus in eastern Europe (Essbauer et al., 2010; Vorou et al., 2008) . Furthermore, it was important to include in our studies an evaluation of how CPXV affects the immune function of two additional human DCs, peripheral blood mDCs and pDCs, primary DCs, which have been infrequently studied in regard to orthopoxvirus effects on their function, partly because the numbers that can be isolated from a unit of blood is less than one million of each. mDCs are closely related functionally and phenotypically to MDDCs, and as shown in our studies, showed relatively few differences in their responses to CPXV. One exception was that while there was a trend to a decrease in the MFI of HLA-DR in MDDCs following a CPXV infection, the difference was statistically significant with mDCs. However, pDCs are both functionally and phenotypically different from MDDCs, and it was important to determine whether an orthopoxvirus might directly stimulate a strong interferon response and/or suppress their response to another viral infectious agent that typically induces a strong interferon response.
We demonstrated that CPXV caused a nonproductive infection in human MDDCs, mDCs and pDCs, without increasing cell death over that of uninfected DCs, even over a period as long as 5 d. The virus failed to productively stimulate PRRs to induce the secretion of cytokines or chemokines. Furthermore, DCs of all three types did not respond to a relevant TLR agonist with appropriate cytokine and chemokine secretion nor stimulate T cells to proliferate if they were exposed to CPXV at the same time the TLR agonist was added to DCs. For pDCs, we were unable to determine conclusively whether the absence of a detectible IFNα response to either CPXV directly or to influenza in the presence of CPXV co-exposure resulted from suppression or was rather the result of secretion of an IFNα interfering substance into the medium. However, as noted in results, at least for pDCs from a few donors, the suppressed IFNα response could not be explained solely as a result of inability to detect this cytokine. However, infected MDDCs and pDCs from all donors secreted significant amounts of an IFNα inhibitor, and could, therefore, be expected to globally interfere with IFNα-mediated antiviral defenses. The failure of CPXV-infected DCs to stimulate an MLR was associated with a) decreased expression of HLA-DR, CD80 and CD86, essential for effective T cell stimulation and b) changes in Fig. 7 . Intracellular viral immune evasion/virulence gene product detected in MDDCS as early as 2 h following CPXV infection. Total cellular extracts were prepared from uninfected DCs or DCs infected with CPXV (moi 10). Proteins were resolved by SDSpolyacrylamide gel electrophoresis (PAGE) on a 12% SDS-PAGE gel and transferred to nitrocellulose filters for immunoblot analysis using anti-CrmA polyclonal antibody (upper panel). The membrane was stripped and β-actin was detected with anti-β-actin (lower panel, AbCam mouse monoclonal clone 8226 IgG1). the morphology of infected DCs that likely interfered with their capacity to interact effectively with responder T cells. Among the morphological changes that we observed in infected DCs, the most unexpected was the presence of syncytial cells in MDDC cultures infected with CPXV. VACV and CPXV do not induce syncytia at neutral pH unless conditions favor the inhibition or inactivation of proteins such as the K2L and A56R proteins that suppress cell fusion (Brum et al., 2003; Ichihashi and Dales, 1971; Law and Smith, 1992; Turner and Moyer, 1992; Wagenaar and Moss, 2007; Zhou et al., 1992) ; but it is possible that there was insufficient K2L and A56R to suppress the fusion of MDDCs abortively infected with CPXV. Of note is that the formation of multinucleated cells (or syncytial cells) by the fusion of virus-infected cells has been reported for several poxviruses, including monkeypox virus (Reed et al., 2004) , volepox and raccoonpox viruses (Knight et al., 1992) , and ectromelia virus (Harper et al., 1978) .
The failure of DCs to respond directly to CPXV with cytokine secretion was almost certainly not due to the lack of a PRR to detect this large dsDNA virus. Various PRRs, including TLR2 (Zhu et al., 2007) , TLR3 (Hutchens et al., 2008) , TLR4 (Hutchens et al., 2008) , TLR8 (Martinez et al., 2010) , TLR9 (Samuelsson et al., 2008 ), TLR2-6, MDA5, NALP3 (Delaloye et al., 2009) , and AIM2 (Hornung et al., 2009 ) have been implicated in host responses to orthopoxviruses. The lack of PRR-mediated responses to CPXV infection of DCs suggests that CPXV is capable of either avoiding stimulating PRR or rapidly disrupting PRR signaling pathways, or both. Support for the reasoning that CPXV might not stimulate PRR was that hiCPXV failed to stimulate DCs to secrete cytokines or chemokines. Support for the possibility that PRR signaling occurred, but was rapidly disrupted, was that exposure to simultaneous CPXV and a TLR agonist exposure suppressed the DC response to the agonist. Similarly, it was recently shown that ectromelia virus (an orthopoxvirus with a genome that is roughly the same size as CPXV) differs from VACV in being able to evade TLR2 recognition (O'Gorman et al., 2010) .
How orthopoxviruses affect DC function has been studied by a number of investigators, because DCs initiate immune responses that must occur to control primary natural orthopoxvirus infections, to prevent new orthopoxviral infections following vaccination and to develop immunity to tumor antigens or antigens of non-poxvirus infections agents expressed in orthopoxvirus vectors. VACV and MVA have been the orthopoxviruses most studied in this regard, and rodent bone marrow-derived DCs and MDDCs derived from human peripheral blood monocytes have been the predominant DCs examined. Our results are consistent with a number of studies that show that an orthopoxvirus infection of DCs is nonproductive (Bronte et al., 1997; Chahroudi et al., 2005; Deng et al., 2006; Drillien et al., 2000; Engelmayer et al., 1999; Jenne et al., 2000; Liu et al., 2005) . Some of these studies determined that early viral proteins were synthesized in DCs, but late proteins were not (Drillien et al., 2000; Jenne et al., 2000) . We found that some late genes were transcribed, but we did not assess whether any proteins were produced. However, the presence of viral inclusions suggests that at least in mDC and pDC, there might have been translation of the late ATI protein (Osterrieder et al., 1994; Patel et al., 1986) . Infection by canarypox virus, VACV or MVA of MDDCs leads to DC apoptosis (Brandler et al., 2010; Chahroudi et al., 2006; Zhang et al., 2007) , and VACV infection of MDDCs leads to loss of viability as measured by trypan blue exclusion (Engelmayer et al., 1999) . In contrast, we found that the numbers of viable DCs (assessed by trypan blue exclusion), was not altered by CPXV infection (Table 1) . Early in our studies, we determined by TUNEL assay that LPS or CPXV treatment of MDDCs resulted in a small percentage, although equivalent, of apoptotic cells (data not shown), suggesting that CPXV in DCs might generate particular strong antiapoptotic mechanisms. As regards the effect of an orthopoxvirus infection on cytokine secretion by DCs, comparable to our studies, a VACV infection of a murine Langerhans cell line failed to induce cytokine secretion and suppressed the ability of these cells to secrete cytokines in response to LPS (Deng et al., 2006) . In another study, VACV-infected human MDDCs failed to secrete cytokines (Drillien et al., 2004) , but whether LPS-induced cytokine secretion was suppressed in infected cells was not tested. In general, our findings that infection of DCs at a moi of 10 CPXV suppresses maturation of immature DCs and their ability to stimulate T cells responses are similar to the findings of others with VACV (Engelmayer et al., 1999; Bonini et al., 2001; Jenne et al., 2000; Li et al., 2005; Wang et al., 2009) . One study demonstrated that VACV abortively infected both immature MDDCs and mature MDDCs, inhibited immature MDDC maturation in the present of monocyte-conditioned medium and suppressed DC-induced T cell responses (Engelmayer et al., 1999) . Another study demonstrated that VACV suppressed not only suppressed LPSinduced maturation of immature MDDCs and their ability to stimulate T cells, but also DC maturation initiated by CD40L, TNFα and polyI:C (Bonini et al., 2001 ). We did not assess the effect of CPXV on mature DCs, but mature DCs are more resistant to VACV infection (Engelmayer et al., 1999) , and infected mature DCs can be engineered to present agent for more effective antigen-induced stimulation of T cell responses (Bonini et al., 2001 ). We could not find any studies that directly examined how CPXV affected human DCs, but an interesting study strongly suggested that as compared to VACV, CPXV markedly inhibited MHC class I antigen presentation in both human and murine antigen presenting cells (Dasgupta et al., 2007) . Thus, our studies are valuable in expanding our understanding of orthopoxviral-DC interactions to include a comprehensive examination of CPXV on human MDDCs as well as to more completely determine how an orthopoxvirus affects human mDC and pDC cytokine and chemokine secretion or stimulation of an MLR. As regards prior studies on human DCs and pDCs, one study noted that human peripheral blood monocytes, B cells, mDCs and pDCs were preferentially infected by VACV and at a moi of 10, 52% of mDCs and 62% of pDCs were infected (Chahroudi et al., 2005) , but the functional outcomes of this infection were not assessed. A recent study in mice showed that a VACV infection of pDCs (generated from bone marrow) at a lower moi of 1 resulted in NF-κB activation and type I IFN production by TLR8 recognizing viral poly (A)/T DNA (Samuelsson et al., 2008) . However, whether directly infected pDCs were the cells that secreted the type I interferons or whether the secretions was from neighboring uninfected cells recognizing non-infectious virions was not assessed. We were interested in the possible mechanisms by which CPXV suppressed MDDC maturation and function, because MDDCs were more readily acquired in sufficient numbers for the designed experiments than mDCs and pDCs. We found that following simultaneously addition of CPXV and LPS to MDDCs, NF-κB nuclear translocation and host cytokine gene expression were inhibited within 1-2 h. We also demonstrated that MVA, a VACV mutant missing many of the immunomodulatory genes possessed by CPXV, did not stimulate cytokine or chemokine secretion by MDDCs nor suppress their LPS-stimulated cytokine and chemokine secretion. Finally, we demonstrated that CPXV-infected MDDCs transcribed over 40 genes that encoded both intracellular and secreted proteins with possible immunomodulatory function. We interpret these findings to indicate that within 1-2 h MDDCs, and probably mDCs and pDCs, suppress both CPXV-induced and TLR-induced innate immune function as a result of the accumulation of early viral gene products on TLR-induced signal transduction and NF-κB dependent transcriptional activation. Consistent with this interpretation, CPXV has been shown to interfere with the activation of NF-κB transcription factors in various other cell types (Oie and Pickup, 2001) , partly through expression of CPXV proteins such as CP77 (Chang et al., 2009; Lynch et al., 2009) , and CPXV006 (Mohamed et al., 2009b) , as well as partly through the expression of a variety of viral proteins including CPXV homologs of the following VACV proteins: A46R and A52R, which interfere with signaling of TIR-domain containing receptors such as IL-1R and TLRs; and N1L, K1L, M2L, and B14R, each of which interfere with components of the canonical NF-κB signaling pathway DiPerna et al., 2004; Gedey et al., 2006; Shisler and Jin, 2004) . These were the CPVX genes CPXV-BR_40, 41, 190, and 208 (M2L, K1L, A52R, and B14R homologs, respectively) detected at 0.5 h and CPXV-BR_37, and 184 (N1L and A46R homologs, respectively) detected at 1.0 h. Inhibition of NF-κB activation not only suppresses cytokine and chemokine secretion, but also affects the expression of surface molecules essential for effective DC stimulation of the MLR. NF-κB is a transcriptional regulator for the co-stimulatory molecules CD80 and CD86 (Ardeshna et al., 2000) , and the viral inhibition of NF-κB activation may contribute to the reduction in these co-stimulatory molecules on the surface of DCs exposed to CPXV. Transcriptional regulation of HLA-DR is mediated by the master co-activator protein MHC class II transactivator protein (CIITA), but promoter-reporter assays demonstrate that NF-κB directly induces HLA-DR promoter activation in response to LPS (Lee et al., 2006) . Thus, the potential interference by at least eight CPXV intracellular proteins of signaling upstream of NF-κB activation may provide an explanation for the absence of perceived signaling by CPXV to activate DCs, the suppression of TLR-agonist induced cytokine secretion and the decreased expression of critical accessory molecules involved in DCinduced T cell stimulation. Secreted CPXV proteins, such as the CrmB, CrmC, CrmD viral receptors for TNF (Hu et al., 1994; Loparev et al., 1998; Smith et al., 1996) , as well as secreted receptors for IL-1β (Spriggs et al., 1992) , IL-18 (Born et al., 2000; Smith et al., 2000) and CD30L (Panus et al., 2002) would also be expected to suppress NF-κB activation by external ligands, although we were unable to consistently demonstrate that supernatants of CPXV-infected MDDCs were capable of suppressing LPS-stimulated cytokine and chemokine secretion. We considered what the role of general suppression of host gene expression might be on the loss of infected DC function described here. Unless infection resulted in rapid virus-induced inhibition of total host and viral protein synthesis, such as can occur in some non-permissive cells (Drillien et al., 1978) , broad suppression of host gene expression usually does not occur until several hours after infection, and is frequently incomplete until the onset of viral late gene expression (Moss, 2007) . Thus, it seems to us that uniform shutdown of protein synthesis doesn't adequately explain the loss of DC functions, but are better attributed to inhibitors of: TLR/IL-1 signaling pathways (Bowie et al., 2000; Harte et al., 2003; Stack et al., 2005) ; NF-kappaB signaling pathways (Chang et al., 2009; Chen et al., 2008; DiPerna et al., 2004; Graham et al., 2008; Lynch et al., 2009; Mohamed et al., 2009a; 2009b; Oie and Pickup, 2001; Shisler and Jin, 2004; Tait et al., 2000) ; caspase-1 and inflammasomes (Johnston et al., 2005; Ray et al., 1992) ; and the presentation of antigens by MHC classes I and II (Alzhanova et al., 2009; Boshkov et al., 1992; Byun et al., 2009; Byun et al., 2007; Dasgupta et al., 2007; Li et al., 2005; Wang et al., 2009) .
The CPXV-induced downregulation of HLA-DR, CD80 and 86 would predictably reduce the capacity of DCs to stimulate allogeneic T cells proliferation, but likely not completely abrogate the MLR as was shown in Fig. 4 . However, the morphologic changes in CPXV-infected DCs shown in Fig. 1 are compatible with the virus inducing cytoskeletal abnormalities that have been shown to interfere with effective DC-T cell physical interactions (Al-Alwan et al., 2001) . Several studies verify that VACV induces significant morphological changes in the infected cells. VACV infection induces early blebbing that is associated with macropinocytosis of the virion (Mercer and Helenius, 2008) . VACV also induces cell motility and cytoskeletal rearrangements, affecting both microfilaments and microtubules (Mercer and Helenius, 2008; Sanderson et al., 1998a Sanderson et al., , 1998b Sanderson and Smith, 1998; Sanderson et al., 1998b; Schramm et al., 2006) . Within 0.5 h of infection of MDDCs, we detected transcripts of the CPVX-BR_59 gene, a homolog of the VACV gene F11L, which plays a role in early actin remodeling and induction of motility by facilitating cell detachment in VACV-infected cells (Mercer and Helenius, 2008) . At least one study has shown that if cortical actin of DCs was disrupted by transfections with Cdc42 and Rax1 dominant negatives, the interaction of DCs and CD8+ T cells was ineffective (Jaksits et al., 2004 ). Therefore, it seems possible that morphologic changes in DCs induced by CPXV infection could have interfered with development of the normal intimate physical interaction between T cells and DCs that leads to the development of the immunological synapse needed for a productive MLR. Thus, the morphologic changes, in addition to the decrease in surface expression of HLA-DR, CD80 and CD86 could explain the profound suppression of the MLR.
Our studies as well as those of others agree that orthopoxvirus infection of DCs compromises their ability to initiate both an innate and an acquired immune response to the virus, but we found that this correlated with a very high infection rate of MDDCs. In vivo, the likelihood that all DCs become simultaneously infected is highly unlikely, except perhaps at sites of severe infection. For example, in an intravenous infection of mice, fewer than 2% of splenic dendritic cells were infected (Yammani et al., 2008) . Therefore, how are studies that show orthopoxviruses markedly depress DC function relevant to understanding natural orthopoxvirus infections or vaccination? We believe that virus-induced immunomodulation of infected DCs is relevant even while other DCs in the infected environment continue to function. We would predict that a virus capable of suppressing the functions of infected DCs would initiate qualitatively and quantitatively impaired innate and acquired immune responses to infection in comparison to a virus incapable of suppressing the functions of any DCs. First, because infected DCs retain an immature DC status with limited ability to present antigens, they might have the effect of tolerizing naïve T cells as well as failing to stimulate a protective immune response in both naïve and memory T cells. One issue is how quickly infected DCs might become unable to present antigen effectively to naïve T cells in an infected draining lymph node. Although some of the data presented involves a 24 h infection of DCs, the data also show that within only a few hours of infection the following occur: 1) the expression of early and late viral genes; 2) the inhibition of transcription of various cytokines, and 3) the inhibition of ligand-induced accumulation of NF-κB within the nucleus, which would suggest that the infected DCs are unable to interact with T cells to yield a productive immune response within hours of infection. However, for DCs that become infected in the periphery early in an infection, there is a time frame required for the infected DCs to reach draining lymph nodes before they can stimulate naïve T cells; this has been shown to occur over a period of several days in the lungs following deposition of a non-replicating antigen (Xia et al., 1995) . Indeed, as discussed above, the cytoskeletal rearrangements in infected cells might preclude the emigration to draining nodes. Still these paralyzed DCs in the periphery would not be expected to present antigen to any virus specific memory T cells that should arrive at the site of infection. Second, in view of the ability of DCs to maintain long-term viability in vitro despite being infected, these cells could serve in vivo as sources of immune regulating virokines for a protracted period, which would be beneficial to the virus. For example, secreted viral products such as INFαR would be expected to affect the development of an immune response generated by uninfected DCs, because INFα can enhance the ability of these cells to stimulate CD4 cells to develop into Th1 cells (Kadowaki et al., 2000) . In sum, with a quantitative loss of immunocompetent DCs and the ability of infected DCs to secrete immunomodulatory proteins, we suspect that the result of the infection of a subset of DCs, even if small, would be to compromise a full immune response. This modulated response would be less able to curtail the proliferation of the virus, which would give the virus an edge over the host. However, if the host were able to eventually mount an effective response, then the infection would end with the host having successfully developed immunity against future orthopoxvirus infections. An advantage to the virus of more prolonged development of immunity is that it has a longer period of effective replication and, therefore, opportunity to reinfect another host. The possible advantage to the host of a modified immune response is to retain antigen longer to result in a more prolonged memory response, once the infection is resolved.
One can extend the discussion to suggest why CPXV and VACV were both effective vaccines, yet were risky for immunosuppressed individuals. The moi per DCs following vaccination might be very high at the local site, but would decrease as the distance from the inoculation site increased. Effective vaccination could still occur despite early "paralysis" of local DCs. Indeed, this lack of function accompanied by secretion of immunomodulators of innate function might allow for more extensive viral replication with associated increased antigen load. Uninfected DCs and sinusoidal APCs present in lymph nodes draining the site of early infection should be capable of taking up viral particles or peptides and effectively presenting them to responder T cells and B cells. Any poxvirus containing apoptotic or necrotic cells would be effectively cross-presented by uninfected DCs to induce IFNγ secreting and cytotoxic CD8 T cells (Larsson et al., 2001) . The ensuing immune response would then be expected to eventually control viral replication. Yet, in immunocompromised hosts in whom the uninfected immune cells are also compromised, or in those in whom skin lesions allow for continuous self-inoculation, VACV vaccination would be expected to be associated with early greater viral replication and more extensive DC infection than in the immunocompetent host. MVA vaccination is associated with many fewer side effects, and, as shown in our studies, even a high rate of DC infection should have little effect on their immune function, at least as measured by their ability to secrete cytokines and chemokines when stimulated by LPS. Therefore, even though replication at the vaccination site would not occur to increase the antigen load as it might for a CPXV or VACV vaccination, all DCs present should be capable of presenting viral antigens.
Although we now have an effective vaccine to prevent smallpox or other emerging orthopoxvirus infection if needed, it remains important to more fully understand how orthopoxviruses cause disease and modulate immune function, particularly as long as sporadic infections with these viruses continue to occur and they are explored as potential vehicles for development of new vaccines.
Conclusions
Our studies demonstrated that the orthopoxvirus, CPXV, failed to stimulate cytokine and chemokine secretion in MDDCs, mDCs and pDCs and profoundly suppressed their immune function as shown by the infected DCs being unable to secrete cytokines and chemokines in response to known TLR agonists and also being unable to stimulate a MLR. The suppression was associated with a nonproductive infection, without loss of DC viability. In an effort to understand the mechanisms, we found that viral immunomodulatory genes were transcribed early in MDDC infection and was associated with the inhibition of NF-κB nuclear translocation and synthesis of cytokine and chemokine transcripts. In support of a role for the immunomodulatory genes in suppressing DC function was that MVA, which has a markedly reduced number of these intact genes, failed to suppress cytokine and chemokine secretion in LPS-stimulated MDDCs.
Materials and methods
Virus preparation
CPXV strain Brighton Red was grown in VeroE6 cells and purified as described by Joklik (Joklik, 1962) . Heat-inactivation (hi) of CPXV in some experiments was performed in a heat block at 57°C for 45 min (Harper et al., 1978) . Plaque forming assays were performed on VeroE6 cells to demonstrate that this treatment reduced the infectious units by at or greater than 1,000,000 fold.
Competitive binding assay 1.5 × 10 5 VeroE6 cells were grown on a monolayer in a 48-well plate and 1.5 × 10 6 hiCPXV virions were added to each well. Live CPXV virions were added in 10-fold dilutions beginning with 1500 PFU, and plaques were allowed to form for 24 h.
Virion carryover
To determine carryover of infectious virions into MLR cultures that might directly affect the T cell responder, MDDCs were cultured overnight in 200 μl samples in 96-well plates (125,000 cells/ml) with CPXV at a multiplicity of infection (moi) of 10 (CPXV PFU per DC) and washed twice in PBS. The pellet was flash frozen in liquid nitrogen twice, resuspended in 100 μl complete DMEM with 2.5%FBS, and viral titer assessed by plaque assay on Vero E6 cells.
Modified virus Ankara (MVA)
MVA was obtained from the Biodefense and Emerging Infections Research Resources Repository, Manassas, VA 20108-4137.
MDDC generation
Monocyte purification was performed as described with minor modifications (Chomarat et al., 2003; Mentzer et al., 1986) . Briefly, buffy coats of human blood (United Blood Services; Albuquerque, NM) were separated on Ficoll-Paque Plus (GE Healthcare; Uppsala, Sweden). The mononuclear fraction was allowed to form aggregates at 4°C and pelleted and then layered over FBS and pelleted again at 4°C. Monocyte-enriched aggregates were washed twice in versene buffer [0.6 mM EDTA in PBS (Gibco; Grand Island, NY)] to disrupt aggregates and resuspended in a small volume of staining buffer (2% FBS/2 mM EDTA in PBS). Monocytes were further enriched though a process of negative selection with magnetic beads labeled with antibodies to CD3, CD16, CD19 and CD56 (Miltenyi Biotec; Auburn, CA) to remove contaminating T cells, PMNs, B cells and NK cells, respectively. Purified monocytes were seeded into 10 cm culture dishes at 2-3 × 10 6 cells/ml in complete RPMI [RPMI 1640 supplemented with 2 mM L-glutamine, 1 mM nonessential amino acids, 1 mM sodium pyruvate, 100 U/ml penicillin and 100 μg/ml streptomycin with 10% heat inactivated FBS and beta-mercaptoethanol (β-ME)]. IL-4 (20 ng/ml) and GM-CSF (100 ng/ml), both from Biosource/ Invitrogen (Carlsbad, CA), were added at 0 time and on day 3, and on day 6 monocyte-derived DCs (MDDCs) were harvested for in vitro studies. MDDCs were cultured in complete RPMI for all experiments.
mDC and pDC isolation
Human mDCs and pDCs were separated based on the differential presence of CD11c and CD123, respectively, and the absence of all lineage markers for non-DC lineage cells (Masten et al., 2006) . mDCs co-express CD11c and HLA-DR, and may or may not express CD123 (Liu et al., 2001; O'Doherty et al., 1994) . Plasmacytoid DCs (pDCs) coexpress CD4, CD123 and HLA-DR, but not CD11c (Bauer et al., 2001; Siegal et al., 1999) . PBMCs were obtained as described above. Anti-CD3, CD14, CD16, CD19, CD56 and Glycophorin A coated magnetic beads (Miltenyi Biotec) were added to PBMCs, which were then magnetically sorted on an AUTO Macs (Miltenyi Biotec), and the unlabeled fraction was collected. For FACS sorting, the negative fraction from magnetic sorting was labeled with fluorescent Abs; i.e., a mix of CD3, CD14, CD16, CD19, CD20, CD56-FITC (lineage markers); CD123-PE, HLA-DR-PerCP, and CD11c-APC (BD Pharmingen; San Jose, CA). Unstained and single-stained (compensation) controls were used to set gates on the MoFlo (Dako Cytomation; Ft. Collins, CO). Gates were set to include DCs based on the absence of lineage markers (lineage-) and the presence of HLA-DR. mDCs were sorted as CD11c+, CD123−, and pDCs as CD11c−, CD123+. mDCs were cultured in complete RPMI, and pDCs were cultured in cRPMI and 10 ng/ml IL-3 (R&D Systems; Minneapolis, MN).
DC viral and TLR agonist exposure
Cells were plated in cell appropriate medium, at a concentration of 1.25 × 10 5 cells/ml in triplicate for each treatment. Treatments included medium (mock), LPS (lipopolysaccharide from Escherichia coli 0111:B4; Sigma-Aldrich, at a final concentration of 1 μg/ml), CPXV [multiplicity of infection (moi) of 10] and influenza A/PR/8/34 H1N1 (Advanced Biotechnologies Inc. Columbia, MD) (moi 10). The CPXV moi 10 was determined to be an appropriate dose in preliminary titration studies that examined moi of 1, 10 and 100. A CPXV moi of 1 did not suppress the TLR agonist response as completely as a moi of 10 or 100. Suppression was not different between a moi 10 and 100. The influenza A moi of 10 was determined as appropriate to stimulate pDCs based on previous studies (Diebold et al., 2004) and confirmed in our laboratory. Cells were incubated at 37°C, 5% CO 2 in a humidified incubator for 24 h.
Morphologic studies
Cytospins were made of MDDCs freshly isolated from cultures; freshly sorted mDCs and pDCs; MDDCs, mDCs and pDCs cultured 24 h in medium; TLR agonist-stimulated MDDCs (LPS), mDCs (LPS) and pDCs (Influenza A) in culture 24 h; and MDDCs, mDCs and pDCs cultured 24 h with CPXV. Cytospins were allowed to dry overnight, stored at − 80°C or fixed and stained with Diff-quick (Dade Behring; Deerfield, IL).
CrmA immunostaining
MDDC cytospins were treated with methyl alcohol for 10 min at 20°C and incubated at 4°C overnight or at room temperature for 2 h in a humidified chamber with a rabbit polyclonal anti-CrmA antibody (1:5000 dilution), washed ×3 for 10 min in 2 mM EDTA in PBS pH 7.4 and incubated in a humidified chamber with Alexa Fluor® 488 conjugate goat anti-rabbit IgG (H + L) [Molecular Probes (Invitrogen) Carlsbad, CA] at a concentration of 0.2 μg/ml for 1 h at 37°C protected from light. Slides are mounted in ProLong® Gold antifade reagent with DAPI from Molecular Probes (Invitrogen) which stains the nucleus and emits blue and then cover-slipped. Epifluorescence images were examined and photographed on a Zeiss Axioskop Epifluorescence Microscope equipped with Zeiss Axiocam HR digital color camera at a magnification of 63× using both the DAPI and FITC filters. SlideBook software (Intelligent Imaging Innovations; Denver, CO) was used to merge images and set compensation controls.
NF-κB immunostaining
MDDCs were co-incubated for 0, 15, 30, 60, 120 and 240 min with LPS or CPXV and LPS. Cytospins were prepared as described for CrmA. Prepared cytospins were incubated in a humidified chamber with a rabbit polyclonal anti-NF-κBp65 antibody -ChIP Grade (ab7970) (Abcam, Cambridge, MA, USA). 1:2500 dilution of the primary antibody resulted in optimal staining. Slides were incubated at 4°C overnight or at room temperature for 2 h. Slides were washed three times for 10 min in 2 mM EDTA in PBS 7.4 pH. The slides were then incubated in a humidified chamber with Alexa Fluor® 488 conjugate goat anti-rabbit IgG (H + L) (Molecular Probes (Invitrogen) Carlsbad, CA, USA) at a concentration of 0.2 μg/ml for 1 h at 37°C protected from light. Slides were mounted and epifluorescent images were visualized as described for CrmA staining above. Replicate slides were prepared for each variable and at least 100 cells were examined for each slide to identify where green fluorescence overlapped the nuclei of each cell as a manifestation of NF-κB nuclear translocation (Supplemental Fig. 2 shows examples of cells with and without nuclear staining for NF-κB.)
Cytokine and chemokine secretion 2.5 × 10 4 cells were stimulated overnight in 200 μl complete RPMI in 96-well round-bottom plates. MDDCs and mDCs received the following treatments: mock (medium only), LPS, CPXV or CPXV + LPS. pDCs received the following treatments: mock, influenza A, CPXV, or CPXV + influenza A. At 24 h, supernatants were collected and stored at − 70°C without removal of viral particles. Multi-analyte profiling was performed using the Luminex LX100 system (software version 1.7) with the XY Platform (Luminex). Acquired fluorescence data were analyzed using StatLia from Brendan Scientific (version 3.2). In initial experiments supernatant concentrations of cytokines (IL-1α, IFNα, IL-12p40, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, GM-CSF, IFNγ and TNFα) and chemokines (RANTES, eotaxin, MIP-1α, MIP-1β, MCP-1, GROα, MCP-2, MCP-3 IP-10 and MIG) were measured by combining single bead kits for IL-1α, IFNα, and IL-12 p40 with a 10-plex cytokine panel and a 10-plex chemokine panel (Biosource; Camirillo, CA or Upstate Biosciences, Charlottsville, VA). Subsequent experiments assessed supernatants for the presence of IL-1β, IL-10, IFNα, IL-6, IL12p40, MIP-1α and TNFα, because these cytokines and chemokines were consistently secreted by MDDCs, mDCs or pDCs in response to the relevant TLR agonist (LPS for MDDCs and mDCs and influenza A for pDCs). IL-8 tended to be secreted at high levels regardless of stimulus.
Mixed leukocyte reaction (MLR)
MDDCs were harvested 24 h after overnight incubation in medium or in medium plus LPS, CPXV, and CPXV + LPS, heat-inactivated (hi) CPXV or hiCPXV + LPS. mDCs were harvested 24 h after overnight incubation in medium only or in medium plus LPS, CPXV or CPXV + LPS; and pDCs were harvested 24 h after overnight incubation in medium or in medium plus influenza A, CPXV or CPXV + influenza A. PBMCs from the buffy coat of peripheral blood were obtained as above, and CD4+ T cells obtained by negative selection using a human CD4+ T cell isolation kit II with an AUTO Macs magnetic cell sorter (Milteny Biotec Inc; Auburn, CA). Graded dilutions of DCs were added to 1.5 × 10 5 allogeneic CD4+ T cells in triplicate in complete medium to flat-bottomed 96-well plates. After 5 d, cultures were pulsed with 1 μCi of [ 3 H]thymidine for the last 19 h of culture, harvested with a PHD cell harvester (Cambridge Technologies; Lexington, MA), and radioactive counts were read on a LS6500 scintillation counter (Beckman/Coulter; Fullerton, CA). The results are expressed as counts per minute (cpm) ± SD of triplicate wells.
Four-color immunophenotyping
Suspensions of purified MDDCs and mDCs were incubated with FcR blocking reagent (Miltenyi Biotec) and stained with the mAbs anti-CD14-FITC (M5E2, mouse IgG2a), anti-HLA-DR-PerCP (L243, mouse IgG2a), anti-CD11c-APC (B-ly6, mouse IgG1) and a PEconjugated mAb for surface molecule expression or controls as follows: anti-CD86 (IT2.2, mouse IgG2b), anti-CD80 (L307.4, mouse IgG1), anti-CD40 (5C3, mouse IgG1), mouse IgG1 (MOPC-21), mouse IgG2b (27-35) or with biotinylated CD205 (DEC205) (MG 38, mouse IgG2b, eBiosciences, San Diego, CA), mouse IgG2b (ebmG2b, eBiosciences), followed by streptavidin-PE for detection. Suspensions of pDCs were treated with FcR blocking reagent and stained with the mAbs anti-CD14-FITC (M5E2, mouse IgG2a), anti-HLA-DR-PerCP (L243, mouse IgG2a), anti-CD123-PE (9F5, mouse IgG1), and an APC-conjugated mAb for the surface molecules expression or controls as follows: anti-BDCA-2 (AC144, mouse IgG1; Miltenyi Biotec), anti-BDCA-4 (ADS-17F6, mouse IgG1, Miltenyi Biotec), mouse IgG1 (MOPC-21) or mouse IgG2b (27-35). Biotinylated anti-CD80 (L307.4, mouse IgG1) and biotinylated anti-CD86 (IT2.2, mouse IgG2b) was detected by adding streptavidin-APC. One set of cells was stained with antibody controls i.e., mouse IgG2a-FITC (G155-178), mouse IgG2a-PerCP (×39), and mouse IgG1-APC (MOPC-21) to set the appropriate gates by flow cytometry. All Abs were purchased from BD Biosciences unless otherwise noted. Cells were stained at 4°C and fixed following washing with 2% paraformaldehyde. Data acquisition was performed on a BD Biosciences FACSCalibur and analysis was performed with WinList software (Verity Software House).
Analysis of cytokine transcripts by RT-PCR
MDDCs were exposed to medium, LPS or CPXV + LPS; and total RNA was extracted at 0, 1, 2, 4, 6, 12 and 24 h post-exposure using RNeasy kit (Qiagen Inc, Valencia, CA). cDNA was synthesized using a high-capacity reverse transcription kit (Applied Biosystems, Foster City, CA) and used as a template for the quantitation of TNFα, MIP-1α and IL-12p40 transcript levels using a Taqman® real-time RT-PCR (Applied Biosystems). Transcript levels of either β-actin or cyclophilin A were used as controls. The fold-change (2 ΔΔCT ) for each transcript was calculated by normalizing C T values to control transcript levels at each time-point followed by the normalization to C T values at 0 h for each treatment.
Viral microarray
Viral microarray slides were printed in the UNM Experimental Biology Laboratory (EBL) in accordance with their standard protocols using a CPXV and VACV-specific oligo nucleotide library of 70-mers. The oligonucleotide sequences were graciously provided by Dr. Kathryn Sykes (Arizona State University) and are as described (Borovkov et al., 2009) . MDDCs were exposed to CPXV for 0, 0.5, 1, 2, 4 and 12 h. RNA was harvested using Trizol reagent (Invitrogen, Carlsbad, CA) and cleaned to remove residual organics using the RNeasy minikit (Qiagen, Valencia, CA). Amino allyl cRNA amplification and aRNA labeling with Cy3 were achieved using the MessageAmp™ II aRNA Amplification Kit (Applied Biosystems/Ambion, Austin, TX) as described by the manufacturer's protocols. Cy3-labeled aRNA was hybridized to microarray slides in the UNM EBL. Microarray slides were scanned to determine signal intensities of Cy3-labeled targets using the GenePix 4000A scanner and data was collected using the GenePix Pro 6 scanning, imaging and quantitation software. The data set was normalized, filtered, and clustered using Acuity. All software and instrumentation was from Molecular Devices (Formerly Axon Technologies, Sunnyvale, CA). Significant gene expression differences were determined by averaging the replicates at each time point. For each CPXV-specific oligonucleotide representing a gene the average signal at each time point was divided by the average signal at the 0 h time to give a "fold over 0 time" expression value. Transcripts that showed an increase of 2.5 fold or greater were considered significant for Table 3 , but fold changes for all CPXV genes are recorded in Supplemental Table 1 , including those that did not achieve a 2.5 fold increase above 0 time.
Western blot
5.0 × 10 5 infected MDDCs were harvested at indicated times, washed with ice-cold PBS, then frozen quickly in liquid nitrogen and lysed with ice-cold RIPA (Radio Immuno Precipitation Assay buffer) buffer (150 mM NaCl, 1.0% NP-40 or Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.00) on ice for 30 min. Cell lysates were centrifuged at 13,000 rpm for 10 min; and the protein fraction was added to a loading buffer containing sodium dodecyl sulfate (SDS) and 2× Laemmli buffer (4% SDS, 10% 2-mercaptoethanol, 20% glycerol, 0.004% bromophenol blue, 0.125 M Tris HCl) and boiled for 5 min. Protein extracts were fractionated by electrophoresis in a 12% SDS-polyacrylamide gel (Bio-Rad Hercules, CA, USA) under reducing conditions and transferred to a polyvinylidene difluoride membrane (PVDF, Bio-Rad Hercules). Membranes were blocked in 5% nonfat milk in Tris-buffered saline, incubated for N2 h at RT or overnight at 4°C with an rabbit anti-CrmA polyclonal antibody, washed, incubated with horseradish peroxidase-conjugated goatanti-rabbit IgG (Promega, Madison, WI, USA, W4011), probed using enhanced chemiluminescence (ECL: Amersham, Little Chalfont, England) and the autoradiograph captured on X-ray film (Bio-Rad Hercules).
Statistical analysis
Statistical analysis was performed as indicated in figure legends using GraphPad Prism Software (GraphPad Software, Inc; San Diego, CA).
Supplementary materials related to this article can be found online at doi:10.1016/j.virol.2011.01.024.
